Oral Semaglutide's Helper Ingredient SNAC Raises Gut and Inflammation Questions in Animal Study

When semaglutide is injected - as with Ozempic or the higher-dose Wegovy injection - it enters the bloodstream directly. The oral tablet version, recently approved in the US, cannot do this on its own: the GLP-1 receptor agonist would be degraded by stomach enzymes before reaching the circulation. The tablet works because of an ingredient called salcaprozate sodium, or SNAC, which protects semaglutide from enzymatic breakdown and facilitates its absorption across the gastric mucosa.

SNAC has been in use for years and is considered safe at approved doses. But as oral semaglutide moves from a niche formulation to a mass-market product taken daily by millions of people - potentially for years - the question of what repeated SNAC exposure does to the gut has received little systematic attention. An animal study from Adelaide University, described as the first in vivo investigation to evaluate repeated SNAC exposure on gut microbiota, metabolic function, and inflammatory outcomes, found a pattern of biological changes that the researchers say warrants further investigation.

What the 21-day animal study found

The study exposed animals to SNAC over 21 days and measured multiple biological endpoints. The findings clustered across several systems:

Gut microbiota: Animals showed lower levels of beneficial bacteria involved in dietary fiber fermentation. The caecum - the section of the large intestine where fiber-fermenting bacteria are concentrated - was smaller in SNAC-exposed animals, suggesting reduced functional capacity for fiber breakdown.

Metabolic byproducts: Short-chain fatty acids, which beneficial gut bacteria produce by fermenting fiber and which help maintain gut barrier integrity and modulate immune responses, were reduced. Short-chain fatty acids include butyrate, propionate, and acetate - compounds with well-established protective roles in gut and systemic health.

Inflammation: Blood inflammatory markers were elevated in SNAC-exposed animals. Liver weight was increased, which can indicate low-grade hepatic inflammation, though liver histology details were not described in the press release.

Brain-derived neurotrophic factor: BDNF, a protein that supports neuronal survival and plasticity and whose levels have been associated with cognitive function, was reduced.

What these findings do and do not establish

The researchers are direct about the limits of this work. These are animal model results, not human data. Standard rodent models used in such studies metabolize and respond to compounds differently than humans, and a 21-day exposure does not replicate the years of daily dosing that characterize clinical obesity treatment.

"Importantly, our findings do not prove that SNAC causes harm in humans," said senior author Paul Joyce, PhD, senior research fellow in the School of Pharmacy and Biomedical Sciences at Adelaide University. "However, they do show that the ingredient enabling these tablets to work may have adverse biological effects beyond drug absorption."

The study also cannot separate the effects of SNAC from any indirect effects caused by altered gastric physiology. SNAC transiently raises gastric pH and locally increases mucosal permeability to enable drug absorption; those transient changes in the gastric environment could themselves affect downstream gut microbiota independently of any direct SNAC toxicity. Untangling those mechanisms requires additional experimental designs.

Why the timing matters

Globally, approximately 890 million adults and 160 million children live with obesity - roughly one in eight people worldwide. The United States has the highest obesity rate among OECD nations, with 43% of adults over 15 meeting the criteria. Semaglutide-based treatments have shown substantial efficacy, and demand has grown sharply. The US approval of oral Wegovy, expected to be cheaper and more convenient than injections, is likely to expand the treatment population substantially.

If oral semaglutide becomes as widespread as its injectable counterparts, SNAC will be among the most consumed pharmaceutical excipients in history. Lead author Amin Ariaee, a PhD candidate in the School of Pharmacy and Biomedical Sciences, framed the motivation accordingly.

"As oral versions become more widely used, we need to understand what repeated, long-term exposure to all ingredients in the pill means for the body - not just the active drug," Ariaee said. "Our study found that SNAC was associated with shifts in potentially harmful gut bacteria, elevated inflammatory markers and depletion of proteins linked to cognitive impairment. These findings warrant further investigation."

What comes next

The Adelaide University group's immediate contribution is establishing that SNAC's biological activity extends beyond its function as an absorption facilitator - that it has measurable downstream effects on gut ecology and systemic markers in an animal model. That is a meaningful baseline finding even without clinical data, because it provides a biological rationale for designing human studies.

Those human studies have not yet been done. Prospective trials comparing gut microbiome composition, inflammatory markers, and metabolic outcomes between patients taking oral versus injectable semaglutide - or between oral semaglutide and placebo - would be necessary to determine whether the animal findings translate to clinical significance. Given the scale of the global obesity treatment market, funding for such studies is the most important next step.